Adjuvant radiotherapy halved recurrence risk after complete resection of atypical meningioma
ROAM/EORTC-1308 improved 5-year disease-free survival from 64.3% to 79.9% after complete resection of WHO grade 2 meningioma.
ROAM/EORTC-1308 improved 5-year disease-free survival from 64.3% to 79.9% after complete resection of WHO grade 2 meningioma.
Unopposed progesterone use was associated with eightfold higher odds of tumor-related visual deficit among women referred for meningioma radiotherapy.
Five-year local control exceeded 89% across proton, photon and stereotactic approaches, with no significant modality effect in meta-regression.
Temporally modulated pulsed radiotherapy achieved a median progression-free survival of 27.2 months in large, previously irradiated recurrent meningiomas.